Finance

Lists
QURE:NASDAQ
Uniqure NV
$20.97
-1.46%
(-0.31) 1D
$20.78
-0.91% (-0.19)
Pre-market
Closed: Oct 14, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QURE...
Open
$21.00
High
$21.75
Low
$20.33
Mkt. cap
1.45B
Avg. vol.
2.83M
Volume
1.82K
52-wk high
$71.50
52-wk low
$8.73
EPS
-$4.05
Beta
1.06
Shares outstanding
69.37M
No. of employees
221
Open
$21.00
High
$21.75
Low
$20.33
Mkt. cap
1.45B
Avg. vol.
2.83M
Volume
1.82K
52-wk high
$71.50
52-wk low
$8.73
EPS
-$4.05
Beta
1.06
Shares outstanding
69.37M
No. of employees
221
News stories
From web sources and news partners
Profile
uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies. Wikipedia
About Uniqure NV
CEOMatt Kapusta
Employees221
Founded1998
Headquarters-
SectorBiotechnology
Websiteuniqure.com
Analyst ratings
Based on 10 analysts giving stock ratings to QURE in the past 3 months
Strong buy
Buy
8
Hold
2
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for QURE in the last 3 months.
Highest
Current $20.97
$80.00 (+281.50%)
Average
$53.57 (+155.46%)
Lowest
$28.00 (+33.52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
UBS
Buy
Initiated
$48.00
+128.9%
10/14/2026
Eliana Merle
Barclays
Hold
Downgraded
$28.00
+33.5%
10/06/2026
Luca Issi
RBC Capital
Buy
Reiterated
$48.00
+128.9%
10/02/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
$31.00
+47.8%
09/30/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$75.00
+257.7%
09/29/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$80.00
+281.5%
09/30/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
09/29/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
-
-
09/29/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
09/02/2026
Sami Corwin
William Blair
Buy
Initiated
$73.00
+248.1%
09/02/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$68.00
+224.3%
07/29/2026
Rudy Li
Wolfe Research
Buy
Upgraded
$65.00
+210%
07/29/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$70.00
+233.8%
06/17/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Upgraded
-
-
06/17/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$37.00
+76.4%
05/05/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$95.00
+353%
05/05/2026
Last report
Jul 29, 2026
Fiscal period
Q2 2026
-€1.07 / -€0.71
-51.25%miss
Revenue / Est. (EUR)
5.13M / 4.32M
+18.66%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.70M
5.57M
3.56M
5.84M
Cost of goods sold
32.25M
40.18M
30.73M
30.66M
Cost of revenue
32.25M
40.18M
30.73M
30.66M
Research and development expenses
695.00K
-5.92M
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.44M
21.61M
20.07M
19.77M
Operating expense
20.67M
15.55M
19.89M
26.13M
Total operating expenses
52.91M
55.73M
50.62M
56.79M
Operating income
-49.21M
-50.16M
-47.06M
-50.95M
Other non operating income
-7.22M
18.13M
3.77M
-15.97M
EBT including unusual items
-71.90M
-41.00M
-53.05M
-79.22M
EBT excluding unusual items
-70.08M
-40.05M
-54.38M
-77.96M
Income tax expense
8.63M
-3.92M
488.00K
1.84M
Effective tax rate
-12.00%
9.55%
-0.92%
-2.32%
Other operating expenses
534.00K
-143.00K
-181.00K
6.36M
Net income
-80.53M
-37.09M
-53.54M
-81.06M
Net profit margin
-2,175.87%
-666.06%
-1,502.95%
-1,387.76%
Earnings per share
-
-
-
-
Interest and investment income
3.50M
5.81M
5.23M
5.05M
Interest expense
-16.72M
-14.57M
-14.03M
-14.37M
Net interest expenses
-13.22M
-8.76M
-8.80M
-9.32M
Depreciation and amortization charges
-
-
-
-
EBITDA
-45.58M
-47.19M
-44.10M
-46.04M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps